| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11307-011-0529-8 |
| P8608 | Fatcat ID | release_7gfi3xyqk5ht5jbfb234mhgdse |
| P698 | PubMed publication ID | 22167582 |
| P2093 | author name string | Cherrie K Donawho | |
| Gerard B Fox | |||
| Mark Day | |||
| Arunava Chakravartty | |||
| Joann P Palma | |||
| Yanping Luo | |||
| Gail Bukofzer | |||
| Martin J Voorbach | |||
| Todd B Cole | |||
| David R Reuter | |||
| Sarah R Mudd | |||
| Paul Tapang | |||
| Kimberley D Holich | |||
| P2860 | cites work | Molecular imaging in drug development | Q22122025 |
| Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development | Q28245741 | ||
| Next generation topoisomerase I inhibitors: Rationale and biomarker strategies | Q29011931 | ||
| Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage | Q34094598 | ||
| 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. | Q34211088 | ||
| A quantitative analysis of the kinetics of the G(2) DNA damage checkpoint system | Q35648439 | ||
| [18F]FLT-PET in oncology: current status and opportunities | Q35964138 | ||
| Using imaging biomarkers to accelerate drug development and clinical trials | Q36039936 | ||
| Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology | Q36420719 | ||
| Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth | Q36468236 | ||
| Imaging and oncologic drug development. | Q36531381 | ||
| Imaging of cell proliferation: status and prospects | Q37181529 | ||
| Irinotecan therapy and molecular targets in colorectal cancer: a systemic review | Q37571729 | ||
| The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models | Q38480031 | ||
| Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging | Q39606309 | ||
| Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. | Q39909714 | ||
| Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. | Q39939997 | ||
| Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport. | Q39960608 | ||
| Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells | Q40099977 | ||
| Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation | Q40426552 | ||
| Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. | Q40474923 | ||
| Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma | Q43097958 | ||
| ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors | Q43236659 | ||
| Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine | Q43611315 | ||
| Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. | Q44112084 | ||
| Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. | Q44128080 | ||
| Early changes in [18F]FLT uptake after chemotherapy: an experimental study | Q44192327 | ||
| Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study | Q46616816 | ||
| PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan | Q46897347 | ||
| In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. | Q53526226 | ||
| Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 | ||
| Rapid rise in FDG uptake in an irradiated human tumour xenograft. | Q55478609 | ||
| Mitotic delay and repair in human lymphocytes | Q71048640 | ||
| Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice | Q74756536 | ||
| P433 | issue | 5 | |
| P921 | main subject | colorectal cancer | Q188874 |
| irinotecan | Q412197 | ||
| pharmacodynamics | Q725307 | ||
| colorectal carcinoma | Q25493920 | ||
| xenograft | Q64148587 | ||
| P304 | page(s) | 617-624 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Molecular Imaging and Biology | Q6895951 |
| P1476 | title | Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model | |
| P478 | volume | 14 |
| Q37474422 | Combined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study |
| Q53110150 | Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT. |
| Q39669240 | Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer |
| Q33889809 | FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study |
| Q39018737 | HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice |
| Q35081130 | Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET |
| Q36177290 | Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity |
| Q47103576 | Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'-deoxy-3'-[18F] fluorothymidine in patients with lung cancer |
| Q26778463 | Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies |
| Q38775709 | Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review |
| Q36894808 | [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941. |
Search more.